Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fresenius Kabi recalls benztropine mesylate injection
Being conducted at the user level, the recall is due to the potential presence of glass particles (glass delamination) in the vials. The product that may appear with
Being conducted at the user level, the recall is due to the potential presence of glass particles (glass delamination) in the vials. The product that may appear with
As per the exclusive marketing agreement, the Herbagenix division of Hemp will distribute the product throughout the US, Canada, and Mexico. Designed to help baby boomers and enhance
Developed by Nitto Denko in partnership with Toa Eiyo, the medicine is marketed by Toa Eiyo, distributed and sold by Astellas Pharma as the world’s first transdermal ß1-blocker
The study compared Eliquis as a single-agent against compared to current standard of care in 5,395 patients with confirmed symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE)
The collaboration will leverage Immunocore’s ImmTAC technology directed towards the cancerous cells avoiding damage to healthy cells and the intracellular changes that occur during cancer or viral infection
Known as ASG-15ME, the ADC aims at the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Seattle Genetics chief operating officer Eric
Janssen Immunology Therapeutic scientists and The Icahn School of Medicine researchers will jointly work to investigate disease triggers, identify new opportunities for therapeutic interventions and create diagnostics to
Approved for manufacturing and distribution, Lyxumia is a first once-daily prandial GLP-1 receptor agonist (RA) offering a new treatment option for the people living in the region with
The completion of the transaction involved AstraZeneca to acquire 100% of Pearl’s shares and provides access to PT003, a probable new treatment for chronic obstructive pulmonary disease (COPD),
The Breakthrough Therapy designation has been granted by the regulator, after vetting the results from the Phase II Study (DMD114117), submitted in April at Cold Spring Harbor. The